JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 62.8%

Neg 0% Neu 0% Pos 62.8%

JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:BCRX) with a Neutral and raises the price target from $12 to $13.